Canada - English - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials

Canada - English - Health Canada

angita pharma inc. - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials

Canada - English - Health Canada

beximco pharmaceuticals canada limited - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials

Canada - English - Health Canada

sanis health inc - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5%

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - thiabendazole - suspension concentrate - thiabendazole thiazole active 500.0 g/l - fungicide - apple | banana | bulb | citrus | corm | mushroom | pear | potato | turf | delicious | golden delicious | granny smith | grapefru - anthracnose, blackend or crown rot | blue and green moulds | blue mould on pome - p. expansum | colletotrichum crown rot | crown rot - verticillium spp. | deightoniella spp. | dollar spot | fusarium basal rot | fusarium crown rot or wilt | fusarium dry rot | fusarium patch | gangrene - phoma exigua | gloeosporium fruit rot | grey mould - botrytis cinerea | penicillium blue mould | silver scurf | squirter | stem end rot - phomopsis citri | wet bubble disease on mushroom | black-end rot | botrytis blight | botrytis rot | bunch rot | crown rot - colletotrichum

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 12.25 mg (equivalent: lenvatinib, qty 10 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; iron oxide yellow; purified talc; iron oxide red; calcium carbonate; propylene glycol; hyprolose; mannitol; potassium hydroxide; titanium dioxide; hypromellose; iron oxide black; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 4.9 mg (equivalent: lenvatinib, qty 4 mg) - capsule, hard - excipient ingredients: iron oxide yellow; propylene glycol; potassium hydroxide; mannitol; iron oxide black; titanium dioxide; hypromellose; purified talc; iron oxide red; calcium carbonate; microcrystalline cellulose; hyprolose; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.,differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - primaquine phosphate, quantity: 13.2 mg (equivalent: primaquine, qty 7.5 mg) - tablet, uncoated - excipient ingredients: wheat starch; povidone; purified water; lactose monohydrate; purified talc; gelatin; magnesium stearate; glycerol - prevention of relapses (radical cure) of malaria caused by p.vivax and p. ovale. adjunctive therapy in the treatment of gametocytemia due to p.falciparum in patients resident in areas receptive to malaria.

Canada - English - Health Canada

sanofi-aventis canada inc - primaquine phosphate - tablet - 26.3mg - primaquine phosphate 26.3mg - antimalarials